MedTrace Logo

Efficacy of Favipiravir Against Severe Ebola Virus Disease

NCT02662855 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2016-01-26

No results posted yet for this study

Summary

The purpose of this study is to explore the therapeutic efficacy of Favipiravir, a broad-spectrum antiviral drug against severe cases of Ebola Virus Disease (EVD), which is the most difficult aspect for clinical management of EVD due to its high fatality rate.

Conditions

  • Ebola Virus Disease

Interventions

OTHER

WHO-recommended therapies

symptomatic and supportive treatments according to the WHO manual

DRUG

Favipiravir

oral administration of Favipiravir tablets

Sponsors & Collaborators

  • Beijing 302 Hospital

    collaborator OTHER

  • 307 Hospital of PLA

    collaborator OTHER

  • Sierra Leone-China Friendship Hospital

    collaborator UNKNOWN

  • Centers for Disease Control and Prevention, China

    collaborator OTHER_GOV

  • Beijing Institute of Pharmacology and Toxicology

    lead OTHER

Principal Investigators

  • Wu Zhong, PhD · Beijing Institute of Pharmacology and Toxicology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-04-30
Completion
2015-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02662855 on ClinicalTrials.gov